Frequently Asked Questions
The global robotic lung biopsy market was valued at USD 385.9 Million in 2022.
The robotic lung biopsy market is expected to grow at a CAGR of 9.20% between 2023 and 2030, reaching USD 714.6 Million in 2030.
Instruments and accessories are the leading segment by product and services, holding over 43% share in terms of value in 2022.
The fiber optic real shape navigation segment governs the demand for robotic lung biopsy in the world, holding a massive share of over 80% in 2022.
The ambulatory surgical center’s segment is expected to post the highest CAGR during the forecast period.
North America is fueling the growth of the robotic lung biopsy industry, with an over one-third share in 2022.
The top players include Intuitive Surgical, Harron Lung Center, Community Health Network, Ethicon Inc. (Johnson & Johnson), Shanghai MicroPort MedBot (Group) Co. Ltd., Noah Medical, and Siemens Healthineers.
The major market drivers are the high use of robots in the healthcare industry and the growing preference for minimally invasive procedures.
The major market restraints are the initial capital price required for purchasing and maintaining such equipment; healthcare organizations with limited budgets may be deterred from implementing robotic medical technology.